Heritage Investors Management Corp Purchases 2,712 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Heritage Investors Management Corp raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,616 shares of the medical research company's stock after purchasing an additional 2,712 shares during the quarter. Heritage Investors Management Corp's holdings in Thermo Fisher Scientific were worth $25,687,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at about $25,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $30,000. Navigoe LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $37,000. Smallwood Wealth Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $37,000. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $43,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on TMO. Stifel Nicolaus decreased their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Argus decreased their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Barclays decreased their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research note on Tuesday, June 24th. Royal Bank Of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $599.30.

Thermo Fisher Scientific Stock Down 2.3%

Shares of NYSE:TMO traded down $9.60 during midday trading on Monday, reaching $405.15. The company had a trading volume of 2,730,401 shares, compared to its average volume of 2,025,879. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The business's 50 day moving average price is $410.38 and its 200 day moving average price is $472.32. The stock has a market cap of $152.94 billion, a PE ratio of 23.76, a P/E/G ratio of 2.21 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.11 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.